Skip to main content

83 Result(s)

within J Stary Remove this filter

Page of 5
and

  1. No Access

    Article

    High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome

    Translocations involving the mixed lineage leukemia (MLL) gene, localized at 11q23, frequently occur in pediatric acute myeloid leukemia (AML). We recently reported differences in prognosis between the different ...

    B V Balgobind, C M Zwaan, D Reinhardt, T J C M Arentsen-Peters, I H I M Hollink… in Leukemia (2010)

  2. No Access

    Article

    EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia

    Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalitie...

    B V Balgobind, S Lugthart, I H Hollink, S T J C M Arentsen-Peters… in Leukemia (2010)

  3. No Access

    Article

    Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

    Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value fo...

    M Brüggemann, A Schrauder, T Raff, H Pfeifer, M Dworzak, O G Ottmann, V Asnafi… in Leukemia (2010)

  4. No Access

    Article

    Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic

    J Stary, Y Jabali, J Trka, O Hrusak, P Gajdos, H Hrstkova, J Sterba, B Blazek… in Leukemia (2010)

  5. No Access

    Article

    Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring

    Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL). Although quantitative detection of...

    M Zaliova, E Fronkova, K Krejcikova, K Muzikova, E Mejstrikova, J Stary, J Trka… in Leukemia (2009)

  6. No Access

    Article

    Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors

    Allogeneic HSCT is a curative treatment for high-risk leukemia. In Europe, approximately 15% of children have an HLA-matched sibling, but in 65–70% HLA allele-matched (9–10/10) unrelated donors (UD) can be ide...

    P Sedlacek, E Mejstrikova, R Formankova, P Keslova… in Bone Marrow Transplantation (2008)

  7. No Access

    Article

    B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL

    Minimal residual disease (MRD) detection using quantification of clone-specific Ig or TCR rearrangements before and after transplantation in children with high-risk ALL is an important predictor of outcome. Th...

    E Fronkova, K Muzikova, E Mejstrikova, M Kovac, R Formankova… in Bone Marrow Transplantation (2008)

  8. No Access

    Article

    T-cell receptor Vβ CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia

    (Very) severe acquired aplastic anemia ((v)SAA) and myelodysplastic syndrome (MDS) are rare diseases in childhood. (V)SAA is a bone marrow (BM) failure syndrome characterized by immune-mediated destruction of ...

    A C H de Vries, A W Langerak, B Verhaaf, C M Niemeyer, J Stary, K Schmiegelow… in Leukemia (2008)

  9. No Access

    Article

    Haematopoietic stem cell transplantation in children in eastern European countries 1985–2004: development, recent activity and role of the EBMT/ESH Outreach Programme

    The paediatric population of 19 eastern European countries amounts to approximately 80 million children. Between 1985 and 2004, the number of centres performing haematopoietic stem cell transplantation (HSCT) ...

    J Wachowiak, M Labopin, M Miano, A Chybicka, J Stary… in Bone Marrow Transplantation (2008)

  10. No Access

    Article

    Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

    The ALL IC-BFM 2002 protocol was created as an alternative to the MRD-based AIEOP-BFM ALL 2000 study, to integrate early response criteria into risk-group stratification in countries not performing routine PCR...

    E Fronkova, E Mejstrikova, S Avigad, K W Chik, L Castillo, S Manor… in Leukemia (2008)

  11. No Access

    Article

    Childhood secondary ALL after ALL treatment

    Data on secondary acute lymphoblastic leukaemia (sALL) following ALL treatment are very rare. However, the incidence might be underestimated as sALLs without a significant lineage shift might automatically be ...

    J Zuna, H Cavé, C Eckert, T Szczepanski, C Meyer, E Mejstrikova, E Fronkova… in Leukemia (2007)

  12. No Access

    Article

    Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia

    C P Kratz, C M Niemeyer, C Thomas, S Bauhuber, V Matejas, E Bergsträsser… in Leukemia (2007)

  13. No Access

    Article

    Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia

    A Yoshimi, M Mohamed, M Bierings, C Urban, E Korthof, M Zecca, K-W Sykora… in Leukemia (2007)

  14. No Access

    Article

    JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia

    M Zecca, G Bergamaschi, C Kratz, E Bergsträßer, C Danesino, P De Filippi… in Leukemia (2007)

  15. No Access

    Article

    Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin

    Human leukocyte antigen (HLA)-matched sibling donor hematopoietic stem cell transplantation (HSCT) is available for only approximately 30% patients needing HSCT. Use of alternative donors is associated with a ...

    P Sedláček, R Formánková, P Keslová, L Šrámková, P Hubáček… in Bone Marrow Transplantation (2006)

  16. No Access

    Article

    Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

    A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease, in relapse af...

    F Millot, J Guilhot, B Nelken, T Leblanc, E S De Bont, A N Békassy, H Gadner… in Leukemia (2006)

  17. No Access

    Article

    Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring

    Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70–90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker an...

    L Boublikova, M Kalinova, J Ryan, F Quinn, A O'Marcaigh, O Smith, P Browne… in Leukemia (2006)

  18. No Access

    Article

    AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

    Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patien...

    U Creutzig, D Reinhardt, S Diekamp, M Dworzak, J Stary, M Zimmermann in Leukemia (2005)

  19. No Access

    Article

    Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment

    D Reinhardt, S Diekamp, C Langebrake, J Ritter, J Stary, M Dworzak, A Schrauder… in Leukemia (2005)

  20. No Access

    Article

    TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL

    E Fronkova, J Madzo, J Zuna, L Reznickova, K Muzikova, O Hrusak, J Stary… in Leukemia (2005)

Page of 5